Recent LYEL News
- Lyell Immunopharma to Participate in BofA Securities Health Care Conference • GlobeNewswire Inc. • 05/07/2024 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/06/2024 12:12:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2024 12:06:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 12:03:04 PM
- Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024 • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting • GlobeNewswire Inc. • 03/05/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 09:07:21 PM
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023 • GlobeNewswire Inc. • 02/28/2024 09:05:00 PM
- Lyell Immunopharma Announces Participation in March Investor Conferences • GlobeNewswire Inc. • 02/26/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 01:24:01 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 01:22:01 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/14/2024 01:19:16 AM
- Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/03/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 01:55:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 01:54:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 01:52:09 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:26:02 PM
- Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma • GlobeNewswire Inc. • 11/09/2023 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2023 09:14:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 09:08:41 PM
- Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023 • GlobeNewswire Inc. • 11/07/2023 09:05:00 PM
- Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing • GlobeNewswire Inc. • 10/31/2023 01:00:00 PM
- Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting • GlobeNewswire Inc. • 09/27/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2023 01:16:07 PM
- Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform • PR Newswire (US) • 09/11/2023 12:00:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM